Posted by Michael Wonder on 12 Mar 2024
bluebird bio announces first outcomes based agreement with Medicaid for sickle cell disease gene therapy
11 March 2024 - bluebird bio today announced it has signed its first Medicaid outcomes based agreement for Lyfgenia (lovotibeglogene autotemcel) with the state of Michigan.
Approximately 50% of individuals living with sickle cell disease in the US are insured by Medicaid.
